+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Next-Generation IVD Market by Product Type, Technology, End User, Application, Test Type, Sample Type - Global Forecast to 2030- Product Image
Next-Generation IVD Market by Product Type, Technology, End User, Application, Test Type, Sample Type - Global Forecast to 2030- Product Image
Sale

Next-Generation IVD Market by Product Type, Technology, End User, Application, Test Type, Sample Type - Global Forecast to 2030

  • PDF Icon

    Report

  • 188 Pages
  • May 2025
  • Region: Global
  • 360iResearch™
  • ID: 5925182
UP TO OFF until Dec 31st 2025
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Next-Generation IVD Market grew from USD 65.60 billion in 2024 to USD 69.24 billion in 2025. It is expected to continue growing at a CAGR of 5.30%, reaching USD 89.44 billion by 2030.

Next-Generation IVD The Dawn of a New Diagnostic Era

The in vitro diagnostics (IVD) sector is on the cusp of unprecedented transformation, driven by technological breakthroughs, evolving patient demands, and global health imperatives. What began as labor-intensive assays has matured into an ecosystem where automation, digital analytics, and molecular precision converge to deliver faster, more accurate diagnostic insights. This evolution is reshaping laboratory workflows, enhancing clinical decision-making, and unlocking new possibilities in personalized medicine.

As next-generation IVD solutions gain momentum, stakeholders across the value chain-from instrument manufacturers to reagent developers and software providers-are recalibrating their strategies to capture emerging growth pockets. This introduction sets the stage for a comprehensive exploration of the forces propelling the market forward, the challenges to be navigated, and the strategies that will define future leaders.

Emerging Technologies Redefining In Vitro Diagnostics

The diagnostic landscape is undergoing transformative shifts as artificial intelligence and machine learning algorithms integrate deeply with laboratory instrumentation. Automated image analysis in digital pathology and advanced data-management platforms are empowering clinicians with actionable insights in real time. Simultaneously, point-of-care devices are becoming increasingly sophisticated, enabling decentralized testing with laboratory-grade accuracy in outpatient clinics and even at-home settings.

In parallel, molecular diagnostics is expanding its footprint beyond polymerase chain reaction to include isothermal amplification methods and next-generation sequencing technologies that detect pathogens and genetic markers with unprecedented sensitivity and speed. The convergence of miniaturized hardware, cloud-based analytics, and interoperable software ecosystems is redefining how diagnostic data is generated, managed, and leveraged for population-level surveillance and individualized care pathways.

Navigating the Ripple Effects of 2025 US Tariffs on IVD Supply Chains

The imposition of new US tariffs in 2025 has created reverberations across the global IVD supply chain. Components and raw materials imported from key manufacturing hubs now carry elevated duties, compelling instrument and reagent producers to revisit sourcing strategies. This recalibration is particularly significant for companies reliant on high-precision optical and electronic parts, where cost increases can swiftly cascade into end-market pricing adjustments.

Manufacturers are responding by diversifying supplier portfolios, establishing regional assembly hubs, and in some cases, reshoring critical production lines to mitigate duty exposure. While short-term margins may be compressed, these strategic moves are laying the groundwork for more resilient operations. Labs and healthcare providers alike will need to balance cost considerations against the imperative for uninterrupted access to cutting-edge diagnostics, underscoring the importance of collaborative planning and transparent communication across the ecosystem.

Unveiling Nuanced Market Segments Driving Growth Opportunities

A granular examination of market segments reveals differentiated growth trajectories. Within the instrument category, chemistry analyzers, immunoassay analyzers, and PCR instruments are each benefitting from technology upgrades that boost throughput and reduce turnaround times. On the consumables side, clinical chemistry reagents, immunoassay reagents, and molecular diagnostics reagents exhibit unique adoption patterns tied to evolving disease screening protocols. Meanwhile, the software and services domain is rapidly expanding as laboratories invest in data management platforms capable of integrating high-volume outputs, supplemented by maintenance services that ensure instrumentation uptime.

Technological segmentation underscores the ascendancy of molecular diagnostics across isothermal amplification, PCR-based workflows, and sequencing-based assays, while clinical chemistry remains anchored by both electrochemical and photometric modalities. Immunoassay techniques spanning CLIA, ELISA, and FIA continue to serve critical roles in disease detection, complemented by culture-based and molecular microbiology tests. End-user insights show that hospital laboratories and reference laboratories constitute the backbone of diagnostic capacity, with secondary and tertiary care hospitals expanding specialized testing programs. Point-of-care settings and research institutes are driving niche adoption of compact, rapid-result platforms for epidemiological monitoring and translational research.

Application areas are diversifying in response to patient needs. Autoimmune disease testing for conditions such as celiac disease, lupus, and rheumatoid arthritis is undergoing modernization, while cardiology panels focused on cardiac markers and lipid profiling gain prominence. Infectious disease diagnostics remain a bedrock application, covering COVID-19, hepatitis, HIV, and tuberculosis, even as neurology assays for Alzheimer’s and Parkinson’s diseases carve out new territory. Oncology testing spans both hematological malignancies and solid tumors, leveraging molecular insights for targeted therapy decisions. Across these applications, test types range from qualitative screens to fully quantitative analyses and semi-quantitative methods, with sample variety extending from blood and saliva to tissue biopsies and urine specimens.

Regional Dynamics Shaping the Global Diagnostic Landscape

Geographic dynamics exert a powerful influence on market potential. In the Americas, the United States leads with substantial investments in innovation and regulatory pathways that favor rapid adoption of next-generation platforms. Canada’s diagnostic infrastructure complements this leadership, while Latin American nations present emerging opportunities driven by public health initiatives and growing private-sector partnerships.

Europe, the Middle East, and Africa form a mosaic of diagnostic landscapes. Western European countries benefit from stringent quality standards and reimbursement frameworks that support advanced assay deployment. In the Middle East, strategic investments in healthcare modernization are catalyzing the rollout of high-throughput laboratory networks, whereas Africa’s diagnostic ecosystem is characterized by initiatives to expand access through portable and resilient testing platforms.

Asia-Pacific is home to some of the fastest-growing diagnostic markets. China’s domestic manufacturers are scaling production of molecular and immunoassay reagents, bolstered by supportive government policies. India’s large patient base and cost-sensitive environment drive demand for affordable, point-of-care solutions, while Japan continues to innovate in high-precision instrumentation. Southeast Asian nations are increasingly integrating advanced diagnostics into their healthcare systems, propelled by rising chronic disease prevalence and pandemic preparedness strategies.

Competitive Strategies of Leading In Vitro Diagnostic Innovators

Leading industry players are pursuing differentiated strategies to capture next-generation IVD opportunities. Major manufacturers are channeling R&D resources toward integrating AI-driven analytics with automated platforms, enhancing both diagnostic accuracy and laboratory efficiency. Concurrently, strategic acquisitions and alliances are broadening product portfolios and expanding geographic reach, allowing companies to address end-to-end diagnostic workflows.

Service offerings are evolving beyond traditional maintenance contracts to include predictive analytics for instrument performance and remote diagnostics, ensuring minimal downtime. In parallel, reagent developers are tailoring formulations for high-sensitivity molecular assays, while software vendors continue to enhance interoperability features within laboratory information management systems. By aligning technology roadmaps with emerging clinical needs-such as rapid pathogen detection and multiplex biomarker panels-market leaders are solidifying their positions in a competitive landscape marked by rapid innovation cycles.

Strategic Imperatives to Stay Ahead in the Next-Gen IVD Market

To thrive in the shifting IVD environment, industry leaders should prioritize investment in digital integration, ensuring that laboratory instruments, data management systems, and cloud platforms operate seamlessly. Establishing diversified supply chains and exploring regional manufacturing partnerships will mitigate exposure to tariff fluctuations and geopolitical disruptions. Companies should also cultivate cross-sector collaborations, working with academic centers and healthcare providers to co-develop and validate novel assays in real-world settings.

Focusing on high-growth application areas-such as oncology molecular profiling and rapid infectious disease panels-can unlock new revenue streams, while modular, upgradeable hardware designs will future-proof instrument lifecycles. Embracing a customer-centric approach by offering customized reagent bundles and outcome-based service models will drive loyalty among diagnostic laboratories and point-of-care networks alike. Finally, maintaining agility in regulatory strategy, and engaging early with authorities on emerging diagnostic modalities, will accelerate time-to-market for breakthrough solutions.

Robust Research Framework Underpinning Comprehensive Market Insights

This report synthesizes insights from a robust research framework combining comprehensive secondary data review with primary interviews across industry stakeholders. Key opinion leaders, including laboratory directors and procurement specialists, provided firsthand perspectives on adoption barriers and technology preferences. Proprietary data models were employed to triangulate findings and ensure consistency across segmentation dimensions.

Analytical rigor was reinforced through a multi-stage validation process, encompassing cross-reference of publicly available financial filings, patent landscapes, and regulatory approvals. The methodology further integrated scenario analysis to assess the impact of tariff shifts and regional policy changes. Quality checks and peer reviews ensured that conclusions reflect the most current market dynamics and maintain the highest degree of reliability for strategic decision-making.

Converging Trends Signal a Transformative Future for In Vitro Diagnostics

The convergence of advanced instrumentation, sophisticated software, and diversified reagent portfolios heralds a transformative era for in vitro diagnostics. As stakeholders navigate tariff pressures and regional disparities, the ability to harness detailed segmentation insights will distinguish winners from also-rans. Leading companies are those that couple technological innovation with strategic supply-chain resilience and customer-focused service models.

Looking ahead, the interplay of molecular diagnostics, AI-powered analytics, and decentralized testing will redefine clinical pathways and public health surveillance. Organizations that proactively align their R&D pipelines with emerging disease burdens and regulatory trends will unlock unparalleled growth. Ultimately, the future of IVD rests on collaborative ecosystems where data, technology, and human expertise converge to deliver timely, accurate, and actionable diagnostic information.

Market Segmentation & Coverage

This research report categorizes to forecast the revenues and analyze trends in each of the following sub-segmentations:
  • Product Type
    • Instruments
      • Chemistry Analyzers
      • Immunoassay Analyzers
      • PCR Instruments
    • Reagents & Kits
      • Clinical Chemistry Reagents
      • Immunoassay Reagents
      • Molecular Diagnostics Reagents
    • Software & Services
      • Data Management Software
      • Maintenance Services
  • Technology
    • Clinical Chemistry
      • Electrochemical
      • Photometric
    • Immunoassay
      • Clia
      • Elisa
      • Fia
    • Microbiology
      • Culture Based
      • Molecular
    • Molecular Diagnostic
      • Isothermal Amplification
      • PCR Based
      • Sequencing Based
  • End User
    • Diagnostic Laboratories
      • Hospital Laboratories
      • Reference Laboratories
    • Hospitals & Clinics
      • Secondary Care Hospitals
      • Tertiary Care Centers
    • Point Of Care
    • Research Institutes
  • Application
    • Autoimmune Diseases
      • Celiac
      • Lupus
      • Rheumatoid Arthritis
    • Cardiology
      • Cardiac Markers
      • Lipids
    • Infectious Diseases
      • COVID-19
      • Hepatitis
      • Hiv
      • Tuberculosis
    • Neurology
      • Alzheimer’s Disease
      • Parkinson’s Disease
    • Oncology
      • Hematological
      • Solid Tumor
  • Test Type
    • Qualitative
    • Quantitative
    • Semi Quantitative
  • Sample Type
    • Blood
    • Saliva
    • Tissue
    • Urine
This research report categorizes to forecast the revenues and analyze trends in each of the following sub-regions:
  • Americas
    • United States
      • California
      • Texas
      • New York
      • Florida
      • Illinois
      • Pennsylvania
      • Ohio
    • Canada
    • Mexico
    • Brazil
    • Argentina
  • Europe, Middle East & Africa
    • United Kingdom
    • Germany
    • France
    • Russia
    • Italy
    • Spain
    • United Arab Emirates
    • Saudi Arabia
    • South Africa
    • Denmark
    • Netherlands
    • Qatar
    • Finland
    • Sweden
    • Nigeria
    • Egypt
    • Turkey
    • Israel
    • Norway
    • Poland
    • Switzerland
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • Indonesia
    • Thailand
    • Philippines
    • Malaysia
    • Singapore
    • Vietnam
    • Taiwan
This research report categorizes to delves into recent significant developments and analyze trends in each of the following companies:
  • F. Hoffmann-La Roche Ltd.
  • Abbott Laboratories
  • Siemens Healthineers AG
  • Danaher Corporation
  • Thermo Fisher Scientific Inc.
  • Becton, Dickinson and Company
  • bioMérieux SA
  • Sysmex Corporation
  • QIAGEN N.V.
  • Mindray Medical International Limited

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Next-Generation IVD Market, by Product Type
8.1. Introduction
8.2. Instruments
8.2.1. Chemistry Analyzers
8.2.2. Immunoassay Analyzers
8.2.3. PCR Instruments
8.3. Reagents & Kits
8.3.1. Clinical Chemistry Reagents
8.3.2. Immunoassay Reagents
8.3.3. Molecular Diagnostics Reagents
8.4. Software & Services
8.4.1. Data Management Software
8.4.2. Maintenance Services
9. Next-Generation IVD Market, by Technology
9.1. Introduction
9.2. Clinical Chemistry
9.2.1. Electrochemical
9.2.2. Photometric
9.3. Immunoassay
9.3.1. Clia
9.3.2. Elisa
9.3.3. Fia
9.4. Microbiology
9.4.1. Culture Based
9.4.2. Molecular
9.5. Molecular Diagnostic
9.5.1. Isothermal Amplification
9.5.2. PCR Based
9.5.3. Sequencing Based
10. Next-Generation IVD Market, by End User
10.1. Introduction
10.2. Diagnostic Laboratories
10.2.1. Hospital Laboratories
10.2.2. Reference Laboratories
10.3. Hospitals & Clinics
10.3.1. Secondary Care Hospitals
10.3.2. Tertiary Care Centers
10.4. Point of Care
10.5. Research Institutes
11. Next-Generation IVD Market, by Application
11.1. Introduction
11.2. Autoimmune Diseases
11.2.1. Celiac
11.2.2. Lupus
11.2.3. Rheumatoid Arthritis
11.3. Cardiology
11.3.1. Cardiac Markers
11.3.2. Lipids
11.4. Infectious Diseases
11.4.1. COVID-19
11.4.2. Hepatitis
11.4.3. Hiv
11.4.4. Tuberculosis
11.5. Neurology
11.5.1. Alzheimer’s Disease
11.5.2. Parkinson’s Disease
11.6. Oncology
11.6.1. Hematological
11.6.2. Solid Tumor
12. Next-Generation IVD Market, by Test Type
12.1. Introduction
12.2. Qualitative
12.3. Quantitative
12.4. Semi Quantitative
13. Next-Generation IVD Market, by Sample Type
13.1. Introduction
13.2. Blood
13.3. Saliva
13.4. Tissue
13.5. Urine
14. Americas Next-Generation IVD Market
14.1. Introduction
14.2. United States
14.3. Canada
14.4. Mexico
14.5. Brazil
14.6. Argentina
15. Europe, Middle East & Africa Next-Generation IVD Market
15.1. Introduction
15.2. United Kingdom
15.3. Germany
15.4. France
15.5. Russia
15.6. Italy
15.7. Spain
15.8. United Arab Emirates
15.9. Saudi Arabia
15.10. South Africa
15.11. Denmark
15.12. Netherlands
15.13. Qatar
15.14. Finland
15.15. Sweden
15.16. Nigeria
15.17. Egypt
15.18. Turkey
15.19. Israel
15.20. Norway
15.21. Poland
15.22. Switzerland
16. Asia-Pacific Next-Generation IVD Market
16.1. Introduction
16.2. China
16.3. India
16.4. Japan
16.5. Australia
16.6. South Korea
16.7. Indonesia
16.8. Thailand
16.9. Philippines
16.10. Malaysia
16.11. Singapore
16.12. Vietnam
16.13. Taiwan
17. Competitive Landscape
17.1. Market Share Analysis, 2024
17.2. FPNV Positioning Matrix, 2024
17.3. Competitive Analysis
17.3.1. F. Hoffmann-La Roche Ltd.
17.3.2. Abbott Laboratories
17.3.3. Siemens Healthineers AG
17.3.4. Danaher Corporation
17.3.5. Thermo Fisher Scientific Inc.
17.3.6. Becton, Dickinson and Company
17.3.7. bioMérieux SA
17.3.8. Sysmex Corporation
17.3.9. QIAGEN N.V.
17.3.10. Mindray Medical International Limited
18. ResearchAI
19. ResearchStatistics
20. ResearchContacts
21. ResearchArticles
22. Appendix
List of Figures
FIGURE 1. NEXT-GENERATION IVD MARKET MULTI-CURRENCY
FIGURE 2. NEXT-GENERATION IVD MARKET MULTI-LANGUAGE
FIGURE 3. NEXT-GENERATION IVD MARKET RESEARCH PROCESS
FIGURE 4. GLOBAL NEXT-GENERATION IVD MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 5. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2030 (%)
FIGURE 8. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY TECHNOLOGY, 2024 VS 2030 (%)
FIGURE 10. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY TECHNOLOGY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 12. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY APPLICATION, 2024 VS 2030 (%)
FIGURE 14. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY TEST TYPE, 2024 VS 2030 (%)
FIGURE 16. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY TEST TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY SAMPLE TYPE, 2024 VS 2030 (%)
FIGURE 18. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY SAMPLE TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. AMERICAS NEXT-GENERATION IVD MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 20. AMERICAS NEXT-GENERATION IVD MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. UNITED STATES NEXT-GENERATION IVD MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 22. UNITED STATES NEXT-GENERATION IVD MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. EUROPE, MIDDLE EAST & AFRICA NEXT-GENERATION IVD MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 24. EUROPE, MIDDLE EAST & AFRICA NEXT-GENERATION IVD MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 25. ASIA-PACIFIC NEXT-GENERATION IVD MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 26. ASIA-PACIFIC NEXT-GENERATION IVD MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 27. NEXT-GENERATION IVD MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 28. NEXT-GENERATION IVD MARKET, FPNV POSITIONING MATRIX, 2024
List of Tables
TABLE 1. NEXT-GENERATION IVD MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL NEXT-GENERATION IVD MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 7. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY INSTRUMENTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY CHEMISTRY ANALYZERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY IMMUNOASSAY ANALYZERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY PCR INSTRUMENTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY REAGENTS & KITS, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY CLINICAL CHEMISTRY REAGENTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY IMMUNOASSAY REAGENTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY MOLECULAR DIAGNOSTICS REAGENTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY REAGENTS & KITS, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY SOFTWARE & SERVICES, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY DATA MANAGEMENT SOFTWARE, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY MAINTENANCE SERVICES, BY REGION, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY CLINICAL CHEMISTRY, BY REGION, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY ELECTROCHEMICAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY PHOTOMETRIC, BY REGION, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY CLINICAL CHEMISTRY, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY IMMUNOASSAY, BY REGION, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY CLIA, BY REGION, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY ELISA, BY REGION, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY FIA, BY REGION, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY IMMUNOASSAY, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY MICROBIOLOGY, BY REGION, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY CULTURE BASED, BY REGION, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY MOLECULAR, BY REGION, 2018-2030 (USD MILLION)
TABLE 34. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY MICROBIOLOGY, 2018-2030 (USD MILLION)
TABLE 35. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY MOLECULAR DIAGNOSTIC, BY REGION, 2018-2030 (USD MILLION)
TABLE 36. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY ISOTHERMAL AMPLIFICATION, BY REGION, 2018-2030 (USD MILLION)
TABLE 37. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY PCR BASED, BY REGION, 2018-2030 (USD MILLION)
TABLE 38. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY SEQUENCING BASED, BY REGION, 2018-2030 (USD MILLION)
TABLE 39. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY MOLECULAR DIAGNOSTIC, 2018-2030 (USD MILLION)
TABLE 40. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 41. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 42. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY HOSPITAL LABORATORIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 43. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY REFERENCE LABORATORIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 44. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2030 (USD MILLION)
TABLE 45. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 46. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY SECONDARY CARE HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 47. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY TERTIARY CARE CENTERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 48. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY HOSPITALS & CLINICS, 2018-2030 (USD MILLION)
TABLE 49. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY POINT OF CARE, BY REGION, 2018-2030 (USD MILLION)
TABLE 50. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
TABLE 51. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 52. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY AUTOIMMUNE DISEASES, BY REGION, 2018-2030 (USD MILLION)
TABLE 53. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY CELIAC, BY REGION, 2018-2030 (USD MILLION)
TABLE 54. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY LUPUS, BY REGION, 2018-2030 (USD MILLION)
TABLE 55. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY RHEUMATOID ARTHRITIS, BY REGION, 2018-2030 (USD MILLION)
TABLE 56. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2030 (USD MILLION)
TABLE 57. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY CARDIOLOGY, BY REGION, 2018-2030 (USD MILLION)
TABLE 58. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY CARDIAC MARKERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 59. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY LIPIDS, BY REGION, 2018-2030 (USD MILLION)
TABLE 60. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY CARDIOLOGY, 2018-2030 (USD MILLION)
TABLE 61. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2030 (USD MILLION)
TABLE 62. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY COVID-19, BY REGION, 2018-2030 (USD MILLION)
TABLE 63. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY HEPATITIS, BY REGION, 2018-2030 (USD MILLION)
TABLE 64. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY HIV, BY REGION, 2018-2030 (USD MILLION)
TABLE 65. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY TUBERCULOSIS, BY REGION, 2018-2030 (USD MILLION)
TABLE 66. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 67. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY NEUROLOGY, BY REGION, 2018-2030 (USD MILLION)
TABLE 68. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY ALZHEIMER’S DISEASE, BY REGION, 2018-2030 (USD MILLION)
TABLE 69. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY PARKINSON’S DISEASE, BY REGION, 2018-2030 (USD MILLION)
TABLE 70. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY NEUROLOGY, 2018-2030 (USD MILLION)
TABLE 71. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2030 (USD MILLION)
TABLE 72. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY HEMATOLOGICAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 73. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY SOLID TUMOR, BY REGION, 2018-2030 (USD MILLION)
TABLE 74. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 75. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 76. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY QUALITATIVE, BY REGION, 2018-2030 (USD MILLION)
TABLE 77. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY QUANTITATIVE, BY REGION, 2018-2030 (USD MILLION)
TABLE 78. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY SEMI QUANTITATIVE, BY REGION, 2018-2030 (USD MILLION)
TABLE 79. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
TABLE 80. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY BLOOD, BY REGION, 2018-2030 (USD MILLION)
TABLE 81. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY SALIVA, BY REGION, 2018-2030 (USD MILLION)
TABLE 82. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY TISSUE, BY REGION, 2018-2030 (USD MILLION)
TABLE 83. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY URINE, BY REGION, 2018-2030 (USD MILLION)
TABLE 84. AMERICAS NEXT-GENERATION IVD MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 85. AMERICAS NEXT-GENERATION IVD MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
TABLE 86. AMERICAS NEXT-GENERATION IVD MARKET SIZE, BY REAGENTS & KITS, 2018-2030 (USD MILLION)
TABLE 87. AMERICAS NEXT-GENERATION IVD MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2030 (USD MILLION)
TABLE 88. AMERICAS NEXT-GENERATION IVD MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 89. AMERICAS NEXT-GENERATION IVD MARKET SIZE, BY CLINICAL CHEMISTRY, 2018-2030 (USD MILLION)
TABLE 90. AMERICAS NEXT-GENERATION IVD MARKET SIZE, BY IMMUNOASSAY, 2018-2030 (USD MILLION)
TABLE 91. AMERICAS NEXT-GENERATION IVD MARKET SIZE, BY MICROBIOLOGY, 2018-2030 (USD MILLION)
TABLE 92. AMERICAS NEXT-GENERATION IVD MARKET SIZE, BY MOLECULAR DIAGNOSTIC, 2018-2030 (USD MILLION)
TABLE 93. AMERICAS NEXT-GENERATION IVD MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 94. AMERICAS NEXT-GENERATION IVD MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2030 (USD MILLION)
TABLE 95. AMERICAS NEXT-GENERATION IVD MARKET SIZE, BY HOSPITALS & CLINICS, 2018-2030 (USD MILLION)
TABLE 96. AMERICAS NEXT-GENERATION IVD MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 97. AMERICAS NEXT-GENERATION IVD MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2030 (USD MILLION)
TABLE 98. AMERICAS NEXT-GENERATION IVD MARKET SIZE, BY CARDIOLOGY, 2018-2030 (USD MILLION)
TABLE 99. AMERICAS NEXT-GENERATION IVD MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 100. AMERICAS NEXT-GENERATION IVD MARKET SIZE, BY NEUROLOGY, 2018-2030 (USD MILLION)
TABLE 101. AMERICAS NEXT-GENERATION IVD MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 102. AMERICAS NEXT-GENERATION IVD MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 103. AMERICAS NEXT-GENERATION IVD MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
TABLE 104. AMERICAS NEXT-GENERATION IVD MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 105. UNITED STATES NEXT-GENERATION IVD MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 106. UNITED STATES NEXT-GENERATION IVD MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
TABLE 107. UNITED STATES NEXT-GENERATION IVD MARKET SIZE, BY REAGENTS & KITS, 2018-2030 (USD MILLION)
TABLE 108. UNITED STATES NEXT-GENERATION IVD MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2030 (USD MILLION)
TABLE 109. UNITED STATES NEXT-GENERATION IVD MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 110. UNITED STATES NEXT-GENERATION IVD MARKET SIZE, BY CLINICAL CHEMISTRY, 2018-2030 (USD MILLION)
TABLE 111. UNITED STATES NEXT-GENERATION IVD MARKET SIZE, BY IMMUNOASSAY, 2018-2030 (USD MILLION)
TABLE 112. UNITED STATES NEXT-GENERATION IVD MARKET SIZE, BY MICROBIOLOGY, 2018-2030 (USD MILLION)
TABLE 113. UNITED STATES NEXT-GENERATION IVD MARKET SIZE, BY MOLECULAR DIAGNOSTIC, 2018-2030 (USD MILLION)
TABLE 114. UNITED STATES NEXT-GENERATION IVD MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 115. UNITED STATES NEXT-GENERATION IVD MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2030 (USD MILLION)
TABLE 116. UNITED STATES NEXT-GENERATION IVD MARKET SIZE, BY HOSPITALS & CLINICS, 2018-2030 (USD MILLION)
TABLE 117. UNITED STATES NEXT-GENERATION IVD MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 118. UNITED STATES NEXT-GENERATION IVD MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2030 (USD MILLION)
TABLE 119. UNITED STATES NEXT-GENERATION IVD MARKET SIZE, BY CARDIOLOGY, 2018-2030 (USD MILLION)
TABLE 120. UNITED STATES NEXT-GENERATION IVD MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 121. UNITED STATES NEXT-GENERATION IVD MARKET SIZE, BY NEUROLOGY, 2018-2030 (USD MILLION)
TABLE 122. UNITED STATES NEXT-GENERATION IVD MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 123. UNITED STATES NEXT-GENERATION IVD MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 124. UNITED STATES NEXT-GENERATION IVD MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
TABLE 125. UNITED STATES NEXT-GENERATION IVD MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 126. CANADA NEXT-GENERATION IVD MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 127. CANADA NEXT-GENERATION IVD MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
TABLE 128. CANADA NEXT-GENERATION IVD MARKET SIZE, BY REAGENTS & KITS, 2018-2030 (USD MILLION)
TABLE 129. CANADA NEXT-GENERATION IVD MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2030 (USD MILLION)
TABLE 130. CANADA NEXT-GENERATION IVD MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 131. CANADA NEXT-GENERATION IVD MARKET SIZE, BY CLINICAL CHEMISTRY, 2018-2030 (USD MILLION)
TABLE 132. CANADA NEXT-GENERATION IVD MARKET SIZE, BY IMMUNOASSAY, 2018-2030 (USD MILLION)
TABLE 133. CANADA NEXT-GENERATION IVD MARKET SIZE, BY MICROBIOLOGY, 2018-2030 (USD MILLION)
TABLE 134. CANADA NEXT-GENERATION IVD MARKET SIZE, BY MOLECULAR DIAGNOSTIC, 2018-2030 (USD MILLION)
TABLE 135. CANADA NEXT-GENERATION IVD MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 136. CANADA NEXT-GENERATION IVD MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2030 (USD MILLION)
TABLE 137. CANADA NEXT-GENERATION IVD MARKET SIZE, BY HOSPITALS & CLINICS, 2018-2030 (USD MILLION)
TABLE 138. CANADA NEXT-GENERATION IVD MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 139. CANADA NEXT-GENERATION IVD MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2030 (USD MILLION)
TABLE 140. CANADA NEXT-GENERATION IVD MARKET SIZE, BY CARDIOLOGY, 2018-2030 (USD MILLION)
TABLE 141. CANADA NEXT-GENERATION IVD MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 142. CANADA NEXT-GENERATION IVD MARKET SIZE, BY NEUROLOGY, 2018-2030 (USD MILLION)
TABLE 143. CANADA NEXT-GENERATION IVD MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 144. CANADA NEXT-GENERATION IVD MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 145. CANADA NEXT-GENERATION IVD MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
TABLE 146. MEXICO NEXT-GENERATION IVD MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 147. MEXICO NEXT-GENERATION IVD MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
TABLE 148. MEXICO NEXT-GENERATION IVD MARKET SIZE, BY REAGENTS & KITS, 2018-2030 (USD MILLION)
TABLE 149. MEXICO NEXT-GENERATION IVD MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2030 (USD MILLION)
TABLE 150. MEXICO NEXT-GENERATION IVD MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 151. MEXICO NEXT-GENERATION IVD MARKET SIZE, BY CLINICAL CHEMISTRY, 2018-2030 (USD MILLION)
TABLE 152. MEXICO NEXT-GENERATION IVD MARKET SIZE, BY IMMUNOASSAY, 2018-2030 (USD MILLION)
TABLE 153. MEXICO NEXT-GENERATION IVD MARKET SIZE, BY MICROBIOLOGY, 2018-2030 (USD MILLION)
TABLE 154. MEXICO NEXT-GENERATION IVD MARKET SIZE, BY MOLECULAR DIAGNOSTIC, 2018-2030 (USD MILLION)
TABLE 155. MEXICO NEXT-GENERATION IVD MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 156. MEXICO NEXT-GENERATION IVD MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2030 (USD MILLION)
TABLE 157. MEXICO NEXT-GENERATION IVD MARKET SIZE, BY HOSPITALS & CLINICS, 2018-2030 (USD MILLION)
TABLE 158. MEXICO NEXT-GENERATION IVD MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 159. MEXICO NEXT-GENERATION IVD MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2030 (USD MILLION)
TABLE 160. MEXICO NEXT-GENERATION IVD MARKET SIZE, BY CARDIOLOGY, 2018-2030 (USD MILLION)
TABLE 161. MEXICO NEXT-GENERATION IVD MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 162. MEXICO NEXT-GENERATION IVD MARKET SIZE, BY NEUROLOGY, 2018-2030 (USD MILLION)
TABLE 163. MEXICO NEXT-GENERATION IVD MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 164. MEXICO NEXT-GENERATION IVD MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 165. MEXICO NEXT-GENERATION IVD MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
TABLE 166. BRAZIL NEXT-GENERATION IVD MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 167. BRAZIL NEXT-GENERATION IVD MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
TABLE 168. BRAZIL NEXT-GENERATION IVD MARKET SIZE, BY REAGENTS & KITS, 2018-2030 (USD MILLION)
TABLE 169. BRAZIL NEXT-GENERATION IVD MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2030 (USD MILLION)
TABLE 170. BRAZIL NEXT-GENERATION IVD MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 171. BRAZIL NEXT-GENERATION IVD MARKET SIZE, BY CLINICAL CHEMISTRY, 2018-2030 (USD MILLION)
TABLE 172. BRAZIL NEXT-GENERATION IVD MARKET SIZE, BY IMMUNOASSAY, 2018-2030 (USD MILLION)
TABLE 173. BRAZIL NEXT-GENERATION IVD MARKET SIZE, BY MICROBIOLOGY, 2018-2030 (USD MILLION)
TABLE 174. BRAZIL NEXT-GENERATION IVD MARKET SIZE, BY MOLECULAR DIAGNOSTIC, 2018-2030 (USD MILLION)
TABLE 175. BRAZIL NEXT-GENERATION IVD MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 176. BRAZIL NEXT-GENERATION IVD MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2030 (USD MILLION)
TABLE 177. BRAZIL NEXT-GENERATION IVD MARKET SIZE, BY HOSPITALS & CLINICS, 2018-2030 (USD MILLION)
TABLE 178. BRAZIL NEXT-GENERATION IVD MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 179. BRAZIL NEXT-GENERATION IVD MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2030 (USD MILLION)
TABLE 180. BRAZIL NEXT-GENERATION IVD MARKET SIZE, BY CARDIOLOGY, 2018-2030 (USD MILLION)
TABLE 181. BRAZIL NEXT-GENERATION IVD MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 182. BRAZIL NEXT-GENERATION IVD MARKET SIZE, BY NEUROLOGY, 2018-2030 (USD MILLION)
TABLE 183. BRAZIL NEXT-GENERATION IVD MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 184. BRAZIL NEXT-GENERATION IVD MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 185. BRAZIL NEXT-GENERATION IVD MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
TABLE 186. ARGENTINA NEXT-GENERATION IVD MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 187. ARGENTINA NEXT-GENERATION IVD MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
TABLE 188. ARGENTINA NEXT-GENERATION IVD MARKET SIZE, BY REAGENTS & KITS, 2018-2030 (USD MILLION)
TABLE 189. ARGENTINA NEXT-GENERATION IVD MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2030 (USD MILLION)
TABLE 190. ARGENTINA NEXT-GENERATION IVD MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 191. ARGENTINA NEXT-GENERATION IVD MARKET SIZE, BY CLINICAL CHEMISTRY, 2018-2030 (USD MILLION)
TABLE 192. ARGENTINA NEXT-GENERATION IVD MARKET SIZE, BY IMMUNOASSAY, 2018-2030 (USD MILLION)
TABLE 193. ARGENTINA NEXT-GENERATION IVD MARKET SIZE, BY MICROBIOLOGY, 2018-2030 (USD MILLION)
TABLE 194. ARGENTINA NEXT-GENERATION IVD MARKET SIZE, BY MOLECULAR DIAGNOSTIC, 2018-2030 (USD MILLION)
TABLE 195. ARGENTINA NEXT-GENERATION IVD MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 196. ARGENTINA NEXT-GENERATION IVD MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2030 (USD MILLION)
TABLE 197. ARGENTINA NEXT-GENERATION IVD MARKET SIZE, BY HOSPITALS & CLINICS, 2018-2030 (USD MILLION)
TABLE 198. ARGENTINA NEXT-GENERATION IVD MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 199. ARGENTINA NEXT-GENERATION IVD MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2030 (USD MILLION)
TABLE 200. ARGENTINA NEXT-GENERATION IVD MARKET SIZE, BY CARDIOLOGY, 2018-2030 (USD MILLION)
TABLE 201. ARGENTINA NEXT-GENERATION IVD MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 202. ARGENTINA NEXT-GENERATION IVD MARKET SIZE, BY NEUROLOGY, 2018-2030 (USD MILLION)
TABLE 203. ARGENTINA NEXT-GENERATION IVD MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 204. ARGENTINA NEXT-GENERATION IVD MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 205. ARGENTINA NEXT-GENERATION IVD MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
TABLE 206. EUROPE, MIDDLE EAST & AFRICA NEXT-GENERATION IVD MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 207. EUROPE, MIDDLE EAST & AFRICA NEXT-GENERATION IVD MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
TABLE 208. EUROPE, MIDDLE EAST & AFRICA NEXT-GENERATION IVD MARKET SIZE, BY REAGENTS & KITS, 2018-2030 (USD MILLION)
TABLE 209. EUROPE, MIDDLE EAST & AFRICA NEXT-GENERATION IVD MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2030 (USD MILLION)
TABLE 210. EUROPE, MIDDLE EAST & AFRICA NEXT-GENERATION IVD MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 211. EUROPE, MIDDLE EAST & AFRICA NEXT-GENERATION IVD MARKET SIZE, BY CLINICAL CHEMISTRY, 2018-2030 (USD MILLION)
TABLE 212. EUROPE, MIDDLE EAST & AFRICA NEXT-GENERATION IVD MARKET SIZE, BY IMMUNOASSAY, 2018-2030 (USD MILLION)
TABLE 213. EUROPE, MIDDLE EAST & AFRICA NEXT-GENERATION IVD MARKET SIZE, BY MICROBIOLOGY, 2018-2030 (USD MILLION)
TABLE 214. EUROPE, MIDDLE EAST & AFRICA NEXT-GENERATION IVD MARKET SIZE, BY MOLECULAR DIAGNOSTIC, 2018-2030 (USD MILLION)
TABLE 215. EUROPE, MIDDLE EAST & AFRICA NEXT-GENERATION IVD MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 216. EUROPE, MIDDLE EAST & AFRICA NEXT-GENERATION IVD MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2030 (USD MILLION)
TABLE 217. EUROPE, MIDDLE EAST & AFRICA NEXT-GENERATION IVD MARKET SIZE, BY HOSPITALS & CLINICS, 2018-2030 (USD MILLION)
TABLE 218. EUROPE, MIDDLE EAST & AFRICA NEXT-GENERATION IVD MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 219. EUROPE, MIDDLE EAST & AFRICA NEXT-GENERATION IVD MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2030 (USD MILLION)
TABLE 220. EUROPE, MIDDLE EAST & AFRICA NEXT-GENERATION IVD MARKET SIZE, BY CARDIOLOGY, 2018-2030 (USD MILLION)
TABLE 221. EUROPE, MIDDLE EAST & AFRICA NEXT-GENERATION IVD MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 222. EUROPE, MIDDLE EAST & AFRICA NEXT-GENERATION IVD MARKET SIZE, BY NEUROLOGY, 2018-2030 (USD MILLION)
TABLE 223. EUROPE, MIDDLE EAST & AFRICA NEXT-GENERATION IVD MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 224. EUROPE, MIDDLE EAST & AFRICA NEXT-GENERATION IVD MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 225. EUROPE, MIDDLE EAST & AFRICA NEXT-GENERATION IVD MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
TABLE 226. EUROPE, MIDDLE EAST & AFRICA NEXT-GENERATION IVD MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 227. UNITED KINGDOM NEXT-GENERATION IVD MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 228. UNITED KINGDOM NEXT-GENERATION IVD MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
TABLE 229. UNITED KINGDOM NEXT-GENERATION IVD MARKET SIZE, BY REAGENTS & KITS, 2018-2030 (USD MILLION)
TABLE 230. UNITED KINGDOM NEXT-GENERATION IVD MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2030 (USD MILLION)
TABLE 231. UNITED KINGDOM NEXT-GENERATION IVD MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 232. UNITED KINGDOM NEXT-GENERATION IVD MARKET SIZE, BY CLINICAL CHEMISTRY, 2018-2030 (USD MILLION)
TABLE 233. UNITED KINGDOM NEXT-GENERATION IVD MARKET SIZE, BY IMMUNOASSAY, 2018-2030 (USD MILLION)
TABLE 234. UNITED KINGDOM NEXT-GENERATION IVD MARKET SIZE, BY MICROBIOLOGY, 2018-2030 (USD MILLION)
TABLE 235. UNITED KINGDOM NEXT-GENERATION IVD MARKET SIZE, BY MOLECULAR DIAGNOSTIC, 2018-2030 (USD MILLION)
TABLE 236. UNITED KINGDOM NEXT-GENERATION IVD MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 237. UNITED KINGDOM NEXT-GENERATION IVD MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2030 (USD MILLION)
TABLE 238. UNITED KINGDOM NEXT-GENERATION IVD MARKET SIZE, BY HOSPITALS & CLINICS, 2018-2030 (USD MILLION)
TABLE 239. UNITED KINGDOM NEXT-GENERATION IVD MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 240. UNITED KINGDOM NEXT-GENERATION IVD MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2030 (USD MILLION)
TABLE 241. UNITED KINGDOM NEXT-GENERATION IVD MARKET SIZE, BY CARDIOLOGY, 2018-2030 (USD MILLION)
TABLE 242. UNITED KINGDOM NEXT-GENERATION IVD MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 243. UNITED KINGDOM NEXT-GENERATION IVD MARKET SIZE, BY NEUROLOGY, 2018-2030 (USD MILLION)
TABLE 244. UNITED KINGDOM NEXT-GENERATION IVD MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 245. UNITED KINGDOM NEXT-GENERATION IVD MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 246. UNITED KINGDOM NEXT-GENERATION IVD MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
TABLE 247. GERMANY NEXT-GENERATION IVD MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 248. GERMANY NEXT-GENERATION IVD MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
TABLE 249. GERMANY NEXT-GENERATION IVD MARKET SIZE, BY REAGENTS & KITS, 2018-2030 (USD MILLION)
TABLE 250. GERMANY NEXT-GENERATION IVD MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2030 (USD MILLION)
TABLE 251. GERMANY NEXT-GENERATION IVD MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 252. GERMANY NEXT-GENERATION IVD MARKET SIZE, BY CLINICAL CHEMISTRY, 2018-2030 (USD MILLION)
TABLE 253. GERMANY NEXT-GENERATION IVD MARKET SIZE, BY IMMUNOASSAY, 2018-2030 (USD MILLION)
TABLE 254. GERMANY NEXT-GENERATION IVD MARKET SIZE, BY MICROBIOLOGY, 2018-2030 (USD MILLION)
TABLE 255. GERMANY NEXT-GENERATION IVD MARKET SIZE, BY MOLECULAR DIAGNOSTIC, 2018-2030 (USD MILLION)
TABLE 256. GERMANY NEXT-GENERATION IVD MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 257. GERMANY NEXT-GENERATION IVD MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2030 (USD MILLION)
TABLE 258. GERMANY NEXT-GENERATION IVD MARKET SIZE, BY HOSPITALS & CLINICS, 2018-2030 (USD MILLION)
TABLE 259. GERMANY NEXT-GENERATION IVD MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 260. GERMANY NEXT-GENERATION IVD MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2030 (USD MILLION)
TABLE 261. GERMANY NEXT-GENERATION IVD MARKET SIZE, BY CARDIOLOGY, 2018-2030 (USD MILLION)
TABLE 262. GERMANY NEXT-GENERATION IVD MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 263. GERMANY NEXT-GENERATION IVD MARKET SIZE, BY NEUROLOGY, 2018-2030 (USD MILLION)
TABLE 264. GERMANY NEXT-GENERATION IVD MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 265. GERMANY NEXT-GENERATION IVD MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 266. GERMANY NEXT-GENERATION IVD MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
TABLE 267. FRANCE NEXT-GENERATION IVD MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 268. FRANCE NEXT-GENERATION IVD MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
TABLE 269. FRANCE NEXT-GENERATION IVD MARKET SIZE, BY REAGENTS & KITS, 2018-2030 (USD MILLION)
TABLE 270. FRANCE NEXT-GENERATION IVD MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2030 (USD MILLION)
TABLE 271. FRANCE NEXT-GENERATION IVD MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 272. FRANCE NEXT-GENERATION IVD MARKET SIZE, BY CLINICAL CHEMISTRY, 2018-2030 (USD MILLION)
TABLE 273. FRANCE NEXT-GENERATION IVD MARKET SIZE, BY IMMUNOASSAY, 2018-2030 (USD MILLION)
TABLE 274. FRANCE NEXT-GENERATION IVD MARKET SIZE, BY MICROBIOLOGY, 2018-2030 (USD MILLION)
TABLE 275. FRANCE NEXT-GENERATION IVD MARKET SIZE, BY MOLECULAR DIAGNOSTIC, 2018-2030 (USD MILLION)
TABLE 276. FRANCE NEXT-GENERATION IVD MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 277. FRANCE NEXT-GENERATION IVD MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2030 (USD MILLION)
TABLE 278. FRANCE NEXT-GENERATION IVD MARKET SIZE, BY HOSPITALS & CLINICS, 2018-2030 (USD MILLION)
TABLE 279. FRANCE NEXT-GENERATION IVD MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 280. FRANCE NEXT-GENERATION IVD MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2030 (USD MILLION)
TABLE 281. FRANCE NEXT-GENERATION IVD MARKET SIZE, BY CARDIOLOGY, 2018-2030 (USD MILLION)
TABLE 282. FRANCE NEXT-GENERATION IVD MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 283. FRANCE NEXT-GENERATION IVD MARKET SIZE, BY NEUROLOGY, 2018-2030 (USD MILLION)
TABLE 284. FRANCE NEXT-GENERATION IVD MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 285. FRANCE NEXT-GENERATION IVD MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 286. FRANCE NEXT-GENERATION IVD MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
TABLE 287. RUSSIA NEXT-GENERATION IVD MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 288. RUSSIA NEXT-GENERATION IVD MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
TABLE 289. RUSSIA NEXT-GENERATION IVD MARKET SIZE, BY REAGENTS & KITS, 2018-2030 (USD MILLION)
TABLE 290. RUSSIA NEXT-GENERATION IVD MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2030 (USD MILLION)
TABLE 291. RUSSIA NEXT-GENERATION IVD MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 292. RUSSIA NEXT-GENERATION IVD MARKET SIZE, BY CLINICAL CHEMISTRY, 2018-2030 (USD MILLION)
TABLE 293. RUSSIA NEXT-GENERATION IVD MARKET SIZE, BY IMMUNOASSAY, 2018-2030 (USD MILLION)
TABLE 294. RUSSIA NEXT-GENERATION IVD MARKET SIZE, BY MICROBIOLOGY, 2018-2030 (USD MILLION)
TABLE 295. RUSSIA NEXT-GENERATION IVD MARKET SIZE, BY MOLECULAR DIAGNOSTIC, 2018-2030 (USD MILLION)
TABLE 296. RUSSIA NEXT-GENERATION IVD MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 297. RUSSIA NEXT-GENERATION IVD MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2030 (USD MILLION)
TABLE 298. RUSSIA NEXT-GENERATION IVD MARKET SIZE, BY HOSPITALS & CLINICS, 2018-2030 (USD MILLION)
TABLE 299. RUSSIA NEXT-GENERATION IVD MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 300. RUSSIA NEXT-GENERATION IVD MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2030 (USD MILLION)
TABLE 301. RUSSIA NEXT-GENERATION IVD MARKET SIZE, BY CARDIOLOGY, 2018-2030 (USD MILLION)
TABLE 302. RUSSIA NEXT-GENERATION IVD MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 303. RUSSIA NEXT-GENERATION IVD MARKET SIZE, BY NEUROLOGY, 2018-2030 (USD MILLION)
TABLE 304. RUSSIA NEXT-GENERATION IVD MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 305. RUSSIA NEXT-GENERATION IVD MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 306. RUSSIA NEXT-GENERATION IVD MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
TABLE 307. ITALY NEXT-GENERATION IVD MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 308. ITALY NEXT-GENERATION IVD MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
TABLE 309. ITALY NEXT-GENERATION IVD MARKET SIZE, BY REAGENTS & KITS, 2018-2030 (USD MILLION)
TABLE 310. ITALY NEXT-GENERATION IVD MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2030 (USD MILLION)
TABLE 311. ITALY NEXT-GENERATION IVD MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 312. ITALY NEXT-GENERATION IVD MARKET SIZE, BY CLINICAL CHEMISTRY, 2018-2030 (USD MILLION)
TABLE 313. ITALY NEXT-GENERATION IVD MARKET SIZE, BY IMMUNOASSAY, 2018-2030 (USD MILLION)
TABLE 314. ITALY NEXT-GENERATION IVD MARKET SIZE, BY MICROBIOLOGY, 2018-2030 (USD MILLION)
TABLE 315. ITALY NEXT-GENERATION IVD MARKET SIZE, BY MOLECULAR DIAGNOSTIC, 2018-2030 (USD MILLION)
TABLE 316. ITALY NEXT-GENERATION IVD MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 317. ITALY NEXT-GENERATION IVD MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2030 (USD MILLION)
TABLE 318. ITALY NEXT-GENERATION IVD MARKET SIZE, BY HOSPITALS & CLINICS, 2018-2030 (USD MILLION)
TABLE 319. ITALY NEXT-GENERATION IVD MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 320. ITALY NEXT-GENERATION IVD MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2030 (USD MILLION)
TABLE 321. ITALY NEXT-GENERATION IVD MARKET SIZE, BY CARDIOLOGY, 2018-2030 (USD MILLION)
TABLE 322. ITALY NEXT-GENERATION IVD MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 323. ITALY NEXT-GENERATION IVD MARKET SIZE, BY NEUROLOGY, 2018-2030 (USD MILLION)
TABLE 324. ITALY NEXT-GENERATION IVD MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 325. ITALY NEXT-GENERATION IVD MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 326. ITALY NEXT-GENERATION IVD MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
TABLE 327. SPAIN NEXT-GENERATION IVD MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 328. SPAIN NEXT-GENERATION IVD MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
TABLE 329. SPAIN NEXT-GENERATION IVD MARKET SIZE, BY REAGENTS & KITS, 2018-2030 (USD MILLION)
TABLE 330. SPAIN NEXT-GENERATION IVD MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2030 (USD MILLION)
TABLE 331. SPAIN NEXT-GENERATION IVD MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 332. SPAIN NEXT-GENERATION IVD MARKET SIZE, BY CLINICAL CHEMISTRY, 2018-2030 (USD MILLION)
TABLE 333. SPAIN NEXT-GENERATION IVD MARKET SIZE, BY IMMUNOASSAY, 2018-2030 (USD MILLION)
TABLE 334. SPAIN NEXT-GENERATION IVD MARKET SIZE, BY MICROBIOLOGY, 2018-2030 (USD MILLION)
TABLE 335. SPAIN NEXT-GENERATION IVD MARKET SIZE, BY MOLECULAR DIAGNOSTIC, 2018-2030 (USD MILLION)
TABLE 336. SPAIN NEXT-GENERATION IVD MARKET SIZE, BY END USER, 2018-203

Companies Mentioned

The companies profiled in this Next-Generation IVD market report include:
  • F. Hoffmann-La Roche Ltd.
  • Abbott Laboratories
  • Siemens Healthineers AG
  • Danaher Corporation
  • Thermo Fisher Scientific Inc.
  • Becton, Dickinson and Company
  • bioMérieux SA
  • Sysmex Corporation
  • QIAGEN N.V.
  • Mindray Medical International Limited

Methodology

Loading
LOADING...

Table Information

Report AttributeDetails
No. of Pages188
PublishedMay 2025
Forecast Period2025 - 2030
Estimated Market Value ( USD ) in 2025 $ 69.24 Billion
Forecasted Market Value ( USD ) by 2030 $ 89.44 Billion
Compound Annual Growth Rate5.3%
Regions CoveredGlobal
No. of Companies Mentioned11

Related Topics

Related Reports

IVD Market Outlook to 2029 - Product Image

IVD Market Outlook to 2029

  • Report
  • 80 Pages
  • Global
From
In Vitro Diagnostics Contract Manufacturing Market Size, Share & Trends Analysis Report By Product (Instruments, Software & Services), By Service, By Technology, By End-use, By Region, And Segment Forecasts, 2025 - 2030 - Product Image

In Vitro Diagnostics Contract Manufacturing Market Size, Share & Trends Analysis Report By Product (Instruments, Software & Services), By Service, By Technology, By End-use, By Region, And Segment Forecasts, 2025 - 2030

  • Report
  • 120 Pages
  • Global
From
IVD & LDT For Autoimmune Diseases Market by Test Type, Technology, Product Type, End User, Application, Sample Type - Global Forecast to 2030 - Product Image

IVD & LDT For Autoimmune Diseases Market by Test Type, Technology, Product Type, End User, Application, Sample Type - Global Forecast to 2030

  • Report
  • 182 Pages
  • Global
From
Next-Generation In-vitro Diagnostics Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2019-2029F - Product Image

Next-Generation In-vitro Diagnostics Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2019-2029F

  • Report
  • 183 Pages
  • Global
From
In-Vitro Diagnostics Market Size and Share Analysis - Growth Trends and Forecast Report 2025-2033 - Product Image

In-Vitro Diagnostics Market Size and Share Analysis - Growth Trends and Forecast Report 2025-2033

  • Report
  • 200 Pages
  • Global
From
Copyright © 2002-2025 Research and Markets. All Rights Reserved.